Altamira Therapeutics Ltd. Files 6-K Report
Ticker: CYTOF · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1601936
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, corporate-update
Related Tickers: ALTA
TL;DR
Altamira Therapeutics (ALTA) filed a 6-K for Q2 2024, mostly boilerplate but confirms reporting status.
AI Summary
Altamira Therapeutics Ltd. filed a Form 6-K on September 24, 2024, reporting for the period ending June 30, 2024. The company, formerly known as Auris Medical Holding Ltd., is a pharmaceutical preparations company incorporated in Bermuda. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides an update on Altamira Therapeutics' reporting status and historical company information, which is important for investors tracking the company's regulatory compliance and corporate structure.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Registrant
- Auris Medical Holding Ltd. (company) — Former company name
- September 24, 2024 (date) — Filing date
- June 30, 2024 (date) — Reporting period end date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information required by Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for the month of September 2024, as a foreign private issuer.
What was Altamira Therapeutics Ltd. formerly known as?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd. and Auris Medical Holding AG.
What is the company's Standard Industrial Classification (SIC) code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Altamira Therapeutics Ltd. incorporated and what is its principal executive office address?
Altamira Therapeutics Ltd. is incorporated in Bermuda, and its principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
Does Altamira Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Altamira Therapeutics Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 379 words · 2 min read · ~1 pages · Grade level 11.9 · Accepted 2024-09-24 08:15:21
Filing Documents
- ea0213577-6k_altamira.htm (6-K) — 19KB
- ea021357701ex99-1_altamira.htm (EX-99.1) — 395KB
- ea021357701ex99-2_altamira.htm (EX-99.2) — 138KB
- ea021357701ex99-3_altamira.htm (EX-99.3) — 148KB
- 0001213900-24-081199.txt ( ) — 3299KB
- ears-20240630.xsd (EX-101.SCH) — 49KB
- ears-20240630_cal.xml (EX-101.CAL) — 36KB
- ears-20240630_def.xml (EX-101.DEF) — 163KB
- ears-20240630_lab.xml (EX-101.LAB) — 350KB
- ears-20240630_pre.xml (EX-101.PRE) — 175KB
- ea0213577-6k_altamira_htm.xml (XML) — 309KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 99.3 Press Release dated September 24, 2024 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 104 Cover Page Interactive Data File formatted as Inline XBRL and contained in 3